Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance of Clinical Remission With Adalimumab in Japanese Subjects With Crohn's Disease
2014-004531-39Phase 2
- Sponsor
- Abbott Laboratories
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Adalimumab maintenance with Placebo (2 arms). Primary endpoint: Clinical remission at Week 52.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2014-004531-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004531-39.